Study on the relationship between IL-17, IL-12p70 and the severity and prognosis of patients with hyperlipidemic acute pancreatitis

doi:10.11958/20220540

Abstract

Abstract:

Objective To explore the relationship between interleukin 17 (IL-17), interleukin 12p70 (IL-12p70) and the severity and prognosis of hyperlipidemic acute pancreatitis. Methods A total of 60 patients with hyperlipidemic acute pancreatitis admitted to the Department of Critical Care Medicine, Fuyang People's Hospital were selected and divided into the mild group (19 cases), the moderate group (27 cases) and the severe group (14 cases) according to the severity of the disease. Serum levels of IL-17 and IL-12p70 were compared between the three groups. The relationship between serum levels of IL-17 and IL-12p70 and the severity of the disease was analyzed. Patients were followed up for 28 days, and the prognosis was analyzed. The influencing factors of death in patients with hyperlipidemic acute pancreatitis were analyzed. Receiver operating characteristic (ROC) curve was used to analyze the predictive value of serum IL-17 and IL-12p70 levels for death in patients with hyperlipidemic acute pancreatitis. Results Serum levels of IL-17 and IL-12p70 were increased sequentially in the mild group, the moderate group and the severe group (all P<0.05). Correlation analysis showed that serum levels of IL-17 and IL-12p70 were positively correlated with disease severity (r_s=0.429, 0.384, both P<0.01). Univariate analysis showed that there were no significant differences in gender, proportion of patients with diabetes, hypertension, coronary heart disease and age, serum procalcitonin (PCT), fasting blood glucose (Glu), total cholesterol (TC) and blood amylase (AMY) levels between the dead patients and the surviving patients (P>0.05). The severe proportion and serum C-reactive protein (CRP), triacylglycerol (TG), IL-17 and IL-12p70 levels were significantly higher in the dead patients than those of the surviving patients (P<0.05). Multivariate analysis showed that the elevated levels of IL-17 and IL-12p70 were independent risk factors for death in patients with hyperlipidemic acute pancreatitis (P<0.05). ROC analysis showed that the best cut-off values of serum IL-17 and IL-12p70 levels for predicting death in patients with hyperlipidemic acute pancreatitis were 331.17 ng/L and 24.60 ng/L, the sensitivity was 85.71% and 78.57%, the specificity was 71.74% and 76.09%, and the area under the curve (AUC) was 0.798 and 0.783, respectively. The combined sensitivity, specificity and AUC were 92.86%, 63.04% and 0.823, respectively. Conclusion Serum IL-17 and IL-12p70 levels are related to the severity and prognosis of hyperlipidemic acute pancreatitis, and clinical detection of their levels has a certain predictive value in predicting the death of patients.

Key words: interleukin-17, interleukin-12, pancreatitis, prognosis, interleukin 12p70, hyperlipidemia acute pancreatitis

CLC Number:

R576

Figures/Tables 5

References 20

[1]	吴林, 孔晓霞, 郑桂贞, 等. 早期CRRT联合前列地尔治疗高脂血症性急性重症胰腺炎[J]. 西部医学, 2022, 34(2):270-275.
	WU L, KONG X X, ZHENG G Z, et al. Prospective study of early CRRT combined with alprostadil in the treatment of hyperlipidemic acute severe pancreatitis[J]. Med J West China, 2022, 34(2):270-275. doi: 10.3969/j.issn.1672-3511.2022.02.023.
[2]	SHAN Y, KONG W, ZHU A, et al. Increased levels of miR-372 correlate with disease progression in patients with hyperlipidemic acute pancreatitis[J]. Exp Ther Med, 2020, 19(6):3845-3850. doi: 10.3892/etm.2020.8609.
[3]	WU Z, WANG X, JIANG X. Study on the mechanism of probucol nanosuspension on hyperlipidemic pancreatitis and regulation of blood lipid function[J]. J Nanosci Nanotechnol, 2021, 21(2):1286-1292. doi: 10.1166/jnn.2021.18663.
[4]	CHEN Y J, LIN T L, CAI Z, et al. Assessment of acute pancreatitis severity via determination of serum levels of hsa-miR-126-5p and IL-6[J]. Exp Ther Med, 2021, 21(1):26. doi: 10.3892/etm.2020. 9458.
[5]	刘蔚, 王天刚, 祝虹霞, 等. 柴黄清胰活血颗粒对重症急性胰腺炎患者辅助性T细胞17及其相关因子的调节作用[J]. 中医临床研究, 2020, 12(29):56-59.
	LIU W, WANG T G, ZHU H X, et al. Regulation effects of Chaihuang Qingyi Huoxue granule on Th17 and the related factors in patients with severe acute pancreatitis[J]. Clinical Journal of Chinese Medicine, 2020, 12(29):56-59. doi: 10.3969/j.issn.1674-7860. 2020.29.020.
[6]	MUNITZ A, EDRY-BOTZER L, ITAN M, et al. Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature[J]. Sci Rep, 2021, 11(1):3461. doi: 10.1038/s41598-021-83019-0.
[7]	王万朋, 张岩, 刘海燕, 等. Th1和Th2细胞与急性胰腺炎严重程度的关系[J]. 中华急诊医学杂志, 2019, 28(7):880-885.
	WANG W P, ZHANG Y, LIU H Y, et al. The role of Th1 and Th2 cells in the severity of acute pancreatitis[J]. Chin J Emerg Med, 2019, 28(7):880-885. doi: 10.3760/cma.j.issn.1671-0282.2019. 07.015.
[8]	中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 中华外科杂志, 2021, 59(7):578-587.
	Chinese Pancreatic Surgery Association, Chinese Society of Surgery, Chinese Medical Association. Guidelines for the diagnosis and treatment of acute pancreatitis in China(2021)[J]. Chin J Surg, 2021, 59(7):578-587. doi: 10.3760/cma.j.cn112139-20210416-00172.
[9]	刁星飞, 王志平, 冯玉兰. 新亚特兰大分类下126例急性胰腺炎CT表现特点及病情严重程度分析[J]. 中国CT和MRI杂志, 2020, 18(1):105-107,117,封4.
	DIAO X F, WANG Z P, FENG Y L. CT findings and severity of acute pancreatitis in 126 cases based on the revised Atlanta classification[J]. Chinese Journal of CT and MRI, 2020, 18(1):105-107,117,cover 4. doi: 10.3969/j.issn.1672- 5131.2020.01.033.
[10]	YANG G, ZHANG X. Trimethylamine N-oxide promotes hyperlipidemia acute pancreatitis via inflammatory response[J]. Can J Physiol Pharmacol, 2022, 100(1):61-67. doi: 10.1139/cjpp-2021-0421.
[11]	刘春雨, 林宁, 熊杰, 等. 高脂血症性急性胰腺炎患者血清miR-345-5p的表达及意义[J]. 解放军医学杂志, 2019, 25(4):318-321.
	LIU C Y, LIN N, XIONG J, et al. Expression and significance of miR-345-5p in serum of patients with hyperlipidemia acute pancreatitis[J]. PLA Medical Journal, 2019, 25(4):318-321. doi: 10.11855/j.issn.0577-7402.2019.04.08.
[12]	BERBERICH A J, ZIADA A, ZOU G Y, et al. Conservative management in hypertriglyceridemia-associated pancreatitis[J]. J Intern Med, 2019, 286(6):644-650. doi: 10.1111/joim.12925.
[13]	荆晓晴, 何永权, 姚丽. 重症急性胰腺炎患者血浆RUNX3、IL-17表达与疾病进展相关性分析[J]. 广东医学, 2021, 42(10):1198-1202.
	JING X Q, HE Y Q, YAO L. Analysis of the correlations between the expressions of RUNX3 and IL-17 in plasma and the progression of severe acute pancreatitis[J]. Guangdong Medical Journal, 2021, 42(10):1198-1202. doi: 10.13820/j.cnki.gdyx. 20200820.
[14]	URAZOVA O I, CHURINA E G, HASANOVA R R, et al. Association between polymorphisms of cytokine genes and secretion of IL-12p70,IL-18,and IL-27 by dendritic cells in patients with pulmonary tuberculosis[J]. Tuberculosis (Edinb), 2019, 115:56-62. doi: 10.1016/j.tube.2019.02.003.
[15]	解松龄, 蒋正, 赵涛, 等. 辅助性T细胞17及其细胞因子在急性胰腺炎患者诊治中的作用[J]. 中华肝胆外科杂志, 2020, 26(2):134-138.
	XIE S L, JIANG Z, ZHAO T, et al. The role of Th17 cells and cytokines in the diagnosis and treatment of acute pancreatitis[J]. Chin J Hepatobiliary Surg, 2020, 26(2):134-138.
[16]	LI X, YUAN X, WANG C. The clinical value of IL-3,IL-4,IL-12p70,IL17A,IFN-γ,MIP-1β,NLR,P-selectin,and TNF-α in differentiating bloodstream infections caused by gram-negative,gram-positive bacteria and fungi in hospitalized patients:An observational study[J]. Medicine (Baltimore), 2019, 98(38):e17315. doi: 10.1097/MD.0000000000017315.
[17]	LI G, CHEN H, LIU L, et al. Role of interleukin-17 in acute pancreatitis[J]. Front Immunol, 2021, 12:674803. doi: 10.3389/fimmu.2021.674803.
[18]	WANG J, XU Y, JING H, et al. RORγt inhibitor SR1001 alleviates acute pancreatitis by suppressing pancreatic IL-17-producing Th17 and γδ-T cells in mice with ceruletide-induced pancreatitis[J]. Basic Clin Pharmacol Toxicol, 2021, 129(5):357-368. doi: 10.1111/bcpt.13642.
[19]	许安文, 刘新梅, 李婷. 丹参酮ⅡA磺酸钠联合乌司他丁治疗高脂血症相关性早期急性胰腺炎的疗效及对患者血清炎性因子的影响[J]. 医学临床研究, 2019, 36(7):1409-1411.
	XU A W, LIU X M, LI T. Efficacy of tanshinone IIA sodium sulfonate combined with ulinastatin in the treatment of hyperlipidemia-related early acute pancreatitis and its effect on serum inflammatory factors in patients[J]. J Clin Res, 2019, 36(7):1409-1411. doi: 10.3969/j.issn.1671-7171.2019.00.000.
[20]	薛红, 明芳, 章颖, 等. IL-34、IL-12P70在慢加急性肝衰竭患者血清中的表达及临床意义[J]. 胃肠病学和肝病学杂志, 2021, 30(10):1162-1165.
	XUE H, MING F, ZHANG Y, et al. The expression and significance of serum IL-34 and IL-12P70 in patients with acute-on-chronic liver failure[J]. Chin J Gastroenterol Hepatol, 2021, 30(10):1162-1165. doi: 10.3969/j.issn.1006-5709.2021.10.018.

组别	n	IL-17	IL-12p70
轻度组	19	235.72±43.05	17.31±3.28
中度组	27	314.69±55.37^a	21.54±3.75^a
重度组	14	386.27±69.82^ab	26.33±4.46^ab
F		30.057^＊＊	22.937^＊＊

组别	n	IL-17	IL-12p70
轻度组	19	235.72±43.05	17.31±3.28
中度组	27	314.69±55.37^a	21.54±3.75^a
重度组	14	386.27±69.82^ab	26.33±4.46^ab
F		30.057^＊＊	22.937^＊＊

组别		n		男性			年龄（岁）		合并糖尿病				合并高血压
死亡组		16		12（75.0）			46.38±7.76		10（62.5）				7（43.8）
生存组		44		29（65.9）			44.72±6.15		25（56.8）				16（36.4）
χ²或t				0.448			0.861		0.156				0.271
组别			合并冠心病					严重程度
组别			合并冠心病					轻度			中度				重度
死亡组			8（50.0）					1（6.2）			8（50.0）				7（43.8）
生存组			19（43.2）					18（40.9）			19（43.2）				7（15.9）
χ²或t			0.220								8.470^＊
组别	CRP（mg/L）					TG（mmol/L）				PCT（µg/L）		Glu（mmol/L）
死亡组	134.29±22.71					29.86±5.09				4.35±0.83		10.34±1.70
生存组	118.56±19.33					25.14±4.23				4.18±0.74		9.65±1.62
χ²或t	2.660^＊					2.852^＊＊				0.762		1.440
组别		TC （mmol/L）			AMY （U/L）				IL-17 （ng/L）					IL-12p70 （ng/L）
死亡组		11.28±2.06			406.58±57.22				371.49±68.64					25.92±4.31
生存组		10.79±1.69			428.93±62.47				294.52±51.07					20.16±3.75
χ²或t		0.936			1.252				33.721^＊＊					5.056^＊＊

组别		n		男性			年龄（岁）		合并糖尿病				合并高血压
死亡组		16		12（75.0）			46.38±7.76		10（62.5）				7（43.8）
生存组		44		29（65.9）			44.72±6.15		25（56.8）				16（36.4）
χ²或t				0.448			0.861		0.156				0.271
组别			合并冠心病					严重程度
组别			合并冠心病					轻度			中度				重度
死亡组			8（50.0）					1（6.2）			8（50.0）				7（43.8）
生存组			19（43.2）					18（40.9）			19（43.2）				7（15.9）
χ²或t			0.220								8.470^＊
组别	CRP（mg/L）					TG（mmol/L）				PCT（µg/L）		Glu（mmol/L）
死亡组	134.29±22.71					29.86±5.09				4.35±0.83		10.34±1.70
生存组	118.56±19.33					25.14±4.23				4.18±0.74		9.65±1.62
χ²或t	2.660^＊					2.852^＊＊				0.762		1.440
组别		TC （mmol/L）			AMY （U/L）				IL-17 （ng/L）					IL-12p70 （ng/L）
死亡组		11.28±2.06			406.58±57.22				371.49±68.64					25.92±4.31
生存组		10.79±1.69			428.93±62.47				294.52±51.07					20.16±3.75
χ²或t		0.936			1.252				33.721^＊＊					5.056^＊＊

影响因素	β	SE	Wald χ²	P	OR（95%CI）
IL-17	1.385	0.417	11.031	<0.001	3.995（1.764~9.046）
IL-12p70	1.406	0.438	10.304	<0.001	4.080（1.729~9.626）
常数项	-22.017	5.826	14.282	<0.001	<0.001